Financials

  • Market Capitalization 44.22 B
  • Employee 2 500
  • Founded 2002
  • CEO Yvonne Greenstreet
  • Website www.alnylam.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BFGNJ5
  • Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Total debt
Free cash flow
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
170.67
Price to sales ratio
14.42

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Haberler